Deucravacitinib (TYK2 inhibitor in MPN)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-24 — Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.: Preclinical mechanistic study (structural + cellular + primary-sample + iPSC evidence) identifies TYK2 as a selective dependency of CALR- and MPL-mutant MPN but not JAK2V617F disease; deucravacitinib suppresses STAT3/5 signaling, reduces ET/PMF colony growth, selectively lowers CALR mutant allele burden, and shows enhanced activity combined with fedratinib. (novelty: 5)
Open questions
Related
Contributing findings
Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.
24-sep-2026
novelty 5
per-area 5
introduces